Current Research Studies

A single-arm, open-label, prospective, multicenter safety study to evaluate the occurrence of essential fatty acid deficiency (EFAD) in pediatric patients with parenteral nutrition-associated cholestasis (PNAC) who require more than eight weeks of Omegaven treatment

Omegaven

Phase: IV
Clinicaltrials.gov ID: NCT06274788

What is the goal of the study?

Multicenter, prospective, open-label, primarily observational safety study designed to evaluate the occurrence of essential fatty acid deficiency (EFAD) in pediatric patients with parenteral nutrition-associated cholestasis (PNAC) who are expected to require more than eight weeks of Omegaven treatment

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Danielle Wendel
Study Team Member: Teresa Chen, [email protected]